drugset
drugset / Trial / NCT01619683

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

NCT01619683 ↗

Phase 3 Completed 300 enrolled Repros Therapeutics Inc.
Non-randomizedParallel-groupSingle-blind

Summary

To determine the effects of 12 months of treatment with Androxal on bone mineral density in men with secondary hypogonadism.

Timeline

Start
2012-09
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Androxal Unknown 12.5 mg Oral
Subject Androxal Unknown 25 mg Oral

Indications

No indication recorded.